Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study
Jochen Seufert,1 Katrin Pegelow,2 Peter Bramlage3 1Division of Endocrinology and Diabetology, Department of Internal Medicine II, University Hospital of Freiburg, Freiburg, 2Sanofi Aventis Deutschland GmbH, Berlin, 3Institut für Pharmakologie und Präventive Medizin, Mahlow, Germany...
Main Authors: | Seufert J, Pegelow K, Bramlage P |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2013-11-01
|
Series: | Vascular Health and Risk Management |
Online Access: | http://www.dovepress.com/efficacy-and-safety-of-insulin-glargine-added-to-a-fixed-dose-combinat-a14980 |
Similar Items
-
Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes
by: Christina S. Kwon, et al.
Published: (2018-02-01) -
Treatment progression in sulfonylurea and dipeptidyl peptidase-4-inhibitor cohorts of type 2 diabetes patients on metformin
by: Peng X, et al.
Published: (2016-08-01) -
Nonglycemic effects of dipeptidyl peptidase-4 inhibitors
by: A S Ametov, et al.
Published: (2013-01-01) -
The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors
by: Na-Hyung Kim, et al.
Published: (2014-01-01) -
On the safety of insulin Glargine
by: Ivan Ivanovich Dedov, et al.
Published: (2009-09-01)